Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Invested Capital (2016 - 2025)

Veracyte (VCYT) has disclosed Invested Capital for 14 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 9.89% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 9.89% year-over-year, with the annual reading at $1.3 billion for FY2025, 9.89% up from the prior year.
  • Invested Capital hit $1.3 billion in Q4 2025 for Veracyte, up from $1.3 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.3 billion in Q4 2025 to a low of $971.2 million in Q2 2021.
  • Historically, Invested Capital has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2021.
  • Biggest five-year swings in Invested Capital: skyrocketed 327.93% in 2021 and later fell 5.4% in 2022.
  • Year by year, Invested Capital stood at $1.1 billion in 2021, then decreased by 1.83% to $1.1 billion in 2022, then decreased by 2.75% to $1.0 billion in 2023, then grew by 13.97% to $1.2 billion in 2024, then grew by 9.89% to $1.3 billion in 2025.
  • Business Quant data shows Invested Capital for VCYT at $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.